Insights on Immuno-Oncology Drug Development and the Field’s True Potential

BOSTON, Mass. – January 6, 2016 – BioPharm Insight, the most comprehensive life science market intelligence and analytics solution, recently released an exclusive report on Immuno-Oncology. The report features in depth coverage of Anti PD-1/PD-L1, CAR-Ts and Vaccines.

While drugs like Bristol-Myers Squibb’s Opdivo and Merck’s Keytruda have thrown the limelight once again on immuno-oncology, read BioPharm Insight’s report to find out what key opinion leaders have to say about their true market potential given associated toxicities.

The report also addresses how physicians will need to adapt to using CAR-Ts in blood cancers and the technology’s potential in brain cancer.

Get the full report -

The Immuno-Oncology report contains information on the companies and drugs listed below.

Companies: Agenus, AstraZeneca, Bavarian Nordic, Bristol-Myers Squibb, Celldex, Inovio Pharmaceuticals, Juno Therapeutics, Kite Pharma, MedImmune, Merck, Novartis, Pfizer, VentiRx Pharmaceuticals

Drugs: Atezolizumab, Avelumab, Durvalumab, INO-3112, Keytruda, Opdivo, Pidilizumab, Prophage, Prostvac, Rintega, Tremelimumab, Yervoy

Get the full story on the Immuno-Oncology landscape as it stands today as it will continue to be a hot industry topic for 2016:

About BioPharm Insight

BioPharm Insight is the most comprehensive life science market intelligence and analytics solution, featuring a team of investigative journalists writing exclusive news and thousands of healthcare data points, aggregated into one centralized source. In addition to the proprietary articles that are consistently being written, BioPharm Insight is currently tracking 615,000 management and R&D contacts, 7,000 biopharma companies with full pipeline data, 350,000 investigational and approved drug profiles, 15,000 M&A and licensing deals, 7,000 extended sales forecasts and epidemiology profiles for hundreds of indications. Learn More: